Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
DNA

DNA - Ginkgo Bioworks Holdings, Inc. Stock Price, Fair Value and News

0.30USD-0.03 (-9.09%)Market Closed

Market Summary

DNA
USD0.30-0.03
Market Closed
-9.09%

DNA Stock Price

View Fullscreen

DNA RSI Chart

DNA Valuation

Market Cap

610.1M

Price/Earnings (Trailing)

-0.71

Price/Sales (Trailing)

2.92

EV/EBITDA

0.29

Price/Free Cashflow

-1.89

DNA Price/Sales (Trailing)

DNA Profitability

EBT Margin

-409.17%

Return on Equity

-86.48%

Return on Assets

-53.98%

Free Cashflow Yield

-52.82%

DNA Fundamentals

DNA Revenue

Revenue (TTM)

208.7M

Rev. Growth (Yr)

-52.98%

Rev. Growth (Qtr)

9.18%

DNA Earnings

Earnings (TTM)

-853.8M

Earnings Growth (Yr)

19.06%

Earnings Growth (Qtr)

21.63%

Breaking Down DNA Revenue

Last 7 days

-6.2%

Last 30 days

-28.6%

Last 90 days

-65.5%

Trailing 12 Months

-88.2%

How does DNA drawdown profile look like?

DNA Financial Health

Current Ratio

5.34

DNA Investor Care

Shares Dilution (1Y)

6.20%

Diluted EPS (TTM)

-0.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024208.7M000
2023390.0M326.0M315.0M251.5M
2022438.1M539.1M527.9M477.7M
2021136.0M195.2M254.5M313.8M
20200065.4M76.7M
201900054.2M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ginkgo Bioworks Holdings, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 02, 2024
coen steven p.
sold
-4,407
0.326
-13,520
see remarks
Jul 02, 2024
dmytruk mark e.
sold
-16,026
0.326
-49,162
see remarks
Jul 01, 2024
coen steven p.
acquired
-
-
29,746
see remarks
Jul 01, 2024
dmytruk mark e.
acquired
-
-
108,126
see remarks
Jun 12, 2024
sloan harry
acquired
-
-
105,263
-
Jun 12, 2024
dekkers marijn e
acquired
-
-
105,263
-
Jun 12, 2024
sankar shyam
acquired
-
-
105,263
-
Jun 12, 2024
henry christian o
acquired
-
-
105,263
-
Jun 12, 2024
kewalramani reshma
acquired
-
-
105,263
-
Jun 12, 2024
hannan kathy hopinkah
acquired
-
-
105,263
-

1–10 of 50

Which funds bought or sold DNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 17, 2024
Priebe Wealth Holdings LLC
reduced
-23.82
-18,053
5,079
-%
Jul 17, 2024
SOA Wealth Advisors, LLC.
reduced
-16.73
-432
136
-%
Jul 17, 2024
KBC Group NV
sold off
-100
-30,000
-
-%
Jul 17, 2024
Ballew Advisors, Inc
added
81.82
-6,518
5,802
-%
Jul 17, 2024
CIGNA INVESTMENTS INC /NEW
sold off
-100
-18,000
-
-%
Jul 16, 2024
GPS Wealth Strategies Group, LLC
unchanged
-
-527
213
-%
Jul 16, 2024
MCIA Inc
reduced
-61.69
-76,508
8,106
-%
Jul 16, 2024
IVC Wealth Advisors LLC
sold off
-100
-14,384
-
-%
Jul 16, 2024
180 WEALTH ADVISORS, LLC
reduced
-14.93
-22,757
6,984
-%
Jul 16, 2024
Fortress Wealth Management, Inc.
unchanged
-
-8,257
3,343
-%

1–10 of 50

Are Funds Buying or Selling DNA?

Are funds buying DNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own DNA
No. of Funds

Unveiling Ginkgo Bioworks Holdings, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 05, 2024
baillie gifford & co
7.87%
134,425,866
SC 13G/A
Feb 14, 2024
knight thomas f. jr.
4.1%
68,328,434
SC 13G/A
Feb 14, 2024
che austin
5.6%
95,898,483
SC 13G/A
Feb 14, 2024
shetty reshma p.
10.5%
188,643,922
SC 13D/A
Feb 14, 2024
kelly jason r
5.0%
85,752,333
SC 13D/A
Feb 14, 2024
viking global investors lp
8.8%
143,085,126
SC 13G/A
Feb 13, 2024
vanguard group inc
8.20%
132,779,676
SC 13G/A
Jan 29, 2024
ark investment management llc
12.26%
198,606,619
SC 13G/A
Jan 29, 2024
baillie gifford & co
14.59%
236,292,183
SC 13G/A
Feb 14, 2023
knight thomas f. jr.
5.0%
74,936,116
SC 13G/A

Recent SEC filings of Ginkgo Bioworks Holdings, Inc.

View All Filings
Date Filed Form Type Document
Jul 18, 2024
144
Notice of Insider Sale Intent
Jul 17, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 15, 2024
144
Notice of Insider Sale Intent
Jul 12, 2024
144
Notice of Insider Sale Intent
Jul 11, 2024
144
Notice of Insider Sale Intent
Jul 10, 2024
144
Notice of Insider Sale Intent
Jul 09, 2024
144
Notice of Insider Sale Intent
Jul 08, 2024
144
Notice of Insider Sale Intent
Jul 05, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Ginkgo Bioworks Holdings, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.5B
6.8B
-8.98% -3.09%
-7.79
6.94
-64.45% -224.75%
29.9B
2.0B
53.85% 15.29%
-90.17
14.95
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
15.8B
2.5B
-0.97% -4.31%
77.01
6.4
13.74% 186.89%
14.7B
3.8B
6.43% 3.96%
19.7
3.9
8.58% 129.81%
MID-CAP
4.9B
107.9M
-6.08% -24.75%
-8.88
48.09
54.84% -28.31%
4.6B
524.1M
-5.24% -6.22%
-11.04
8.79
394.93% 39.61%
3.9B
251.0M
7.93% 10.52%
-13.15
15.52
73.58% -86.73%
3.4B
240.7M
17.18% -20.08%
-7.25
12.77
-1.03% -213.92%
3.0B
813.8M
21.05% -43.59%
-1.7K
3.65
56.43% 98.83%
2.1B
996.6M
8.34% 84.22%
-5.26
2.1
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
11.69% 23.21%
30.33
4.8
60.38% -34.49%
565.8M
881.7K
20.84% 614.44%
-16.76
481.06
-77.61% 33.36%
269.0M
4.2M
21.26% 49.14%
-2.15
64.66
-66.30% 48.24%
18.2M
2.1M
-7.46% -80.82%
-0.79
7.61
-13.45% 69.54%

Ginkgo Bioworks Holdings, Inc. News

Latest updates
Defense World42 hours ago
MarketBeat16 Jul 202407:34 pm
American Banking and Market News15 Jul 202404:06 pm
Genetic Engineering & Biotechnology News28 Jun 202407:00 am
The Motley Fool2 months ago

Ginkgo Bioworks Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Revenue9.2%37,944,00034,755,00055,430,00080,568,00080,702,00098,285,00066,398,000144,618,000168,405,000148,494,00077,610,00043,636,00044,097,00028,699,50013,302,000-
Operating Expenses1.4%215,946,000212,872,000341,823,000264,719,000296,447,000329,149,000721,336,000792,397,000843,776,0001,833,229,000104,282,000103,581,000101,212,000-47,715,000-
  S&GA Expenses-21.2%70,287,00089,223,00082,028,000102,341,000111,433,000121,383,000435,221,000438,427,000434,768,000781,626,00028,959,00034,440,00017,927,0005,0009,876,000-
  R&D Expenses-136,457,000-156,662,000144,282,000162,639,000177,548,000261,460,000290,059,000323,576,000985,025,00053,021,00052,031,00059,585,000-36,070,000-
EBITDA Margin-16.1%-3.80-3.27-2.41-3.52-4.27-4.35-6.61-5.44-5.30-5.76-0.43-0.56-0.80-1.42-1.63-1.97
Interest Expenses126.7%11,711,000-43,821,00015,020,00014,349,00014,545,000-8,538,0006,380,0002,264,000-177,0003,854,000-528,000-478,000-475,000-8,293,000-
Income Taxes115.7%31,000-198,000-22,00067,00082,000-14,770,000-28,000-45,000-184,000-683,000-207,000-431,000-159,000-6,000-
Earnings Before Taxes21.7%-165,880,000-211,892,000-302,913,000-173,248,000-204,887,000-187,848,000-670,159,000-670,615,000-592,777,000-1,605,678,000-102,612,000-54,895,000-74,937,000--26,120,000-
EBT Margin-15.2%-4.09-3.55-2.76-3.79-4.44-4.44-6.70-5.51-5.38-5.86-0.49-0.64-0.92-1.63-1.83-2.21
Net Income21.6%-165,911,000-211,694,000-302,891,000-173,315,000-204,969,000-175,468,000-670,131,000-668,825,000-590,505,000-1,600,656,000-101,881,000-53,941,000-73,569,000-5,000-26,055,000-
Net Income Margin-15.2%-4.09-3.55-2.72-3.75-4.41-4.41-6.69-5.49-5.36-5.83-0.90-0.79-0.94-1.05-1.82-2.20
Free Cashflow-56.6%-95,969,000-61,277,000-77,932,000-87,066,000-110,026,000-130,176,000-41,834,000-108,981,000-23,478,000-170,655,000-10,673,000-58,945,000-70,066,000---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42019Q4
Assets-5.0%1,5821,6652,0262,2922,4172,5391,8711,9942,0582,0712,1511,7261,728675697
  Current Assets-9.9%9031,0021,1421,2231,3271,4501,4621,5991,7061,7231,8111.003.00427512
    Cash Equivalents-11.0%8409441,0491,1061,2061,3161,3031,3771,4931,5501,739236308381495
  Inventory---0.000.003.004.006.008.009.003.003.00--3.00-
  Net PPE4.1%196188202294314315188176149146143--12163.00
  Goodwill-2.7%48.0049.0058.0059.0059.0060.0029.0031.0021.0021.0017.00--2.002.00
Liabilities4.6%594568774788810803431427444504533255150205195
  Current Liabilities3.2%16916416816319217312513515913590.005.001.0073.0040.00
Shareholder's Equity-10.0%9871,0971,2531,5041,6081,7361,4441,5721,6191,5671,618356396470502
  Retained Earnings-3.1%-5,456-5,290-5,078-4,775-4,602-4,397-4,222-3,557-2,888-2,297-697-1015.00-467-341
  Additional Paid-In Capital0.9%6,4456,3866,3346,2816,2126,1365,6695,0984,4713,8052,250106-929-
Shares Outstanding1.6%2,0342,0011,9731,9241,9151,8921,6201,6141,6071,3601,3241,2911,2901,2751,149
Minority Interest-------5.0032.0033.0062.0066.00--9.009.00
Float----2,433---2,392---251---
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Cashflow From Operations-54.3%-89.26-57.83-73.55-73.53-90.58-104-28.36-99.41-19.90-165-5.23-34.91-48.13---
  Share Based Compensation-4.8%41.0043.0053.0061.0073.00108563607653-0.0015.000.00---
Cashflow From Investing74.1%-12.11-46.67-3.38-11.22-19.4130.00-46.49-14.66-35.984.00-30.51-23.93-23.05---
Cashflow From Financing-33.7%-0.84-0.63-0.31-1.38-0.8998.00-0.39-0.84-1.19-11.041,548-2.12-0.43---
  Buy Backs-----------25.00-----
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

DNA Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenue$ 37,944$ 80,702
Costs and operating expenses:  
Research and development136,457162,639
General and administrative70,287111,433
Total operating expenses215,946296,447
Loss from operations(178,002)(215,745)
Other income (expense):  
Interest income, net11,71114,545
Loss on equity method investments0(1,449)
Loss on investments(2,544)(6,370)
Change in fair value of warrant liabilities9401,204
Other income, net2,0152,928
Total other income (expense)12,12210,858
Loss before income taxes(165,880)(204,887)
Income tax expense3182
Net loss$ (165,911)$ (204,969)
Net loss per share, basic (in dollars per share)$ (0.08)$ (0.11)
Net loss per share, diluted (in dollars per share)$ (0.08)$ (0.11)
Weighted average common shares outstanding:  
Basic (in shares)2,004,460,0001,914,963,000
Diluted (in shares)2,005,336,0001,916,637,000
Comprehensive loss:  
Net loss$ (165,911)$ (204,969)
Other comprehensive (loss) income:  
Foreign currency translation adjustment(3,035)1,018
Total other comprehensive (loss) income(3,035)1,018
Comprehensive loss(168,946)(203,951)
Cell Engineering  
Total revenue[1]27,88934,096
Product  
Total revenue011,666
Costs and operating expenses:  
Cost of Biosecurity revenue04,541
Service  
Total revenue10,05534,940
Costs and operating expenses:  
Cost of Biosecurity revenue$ 9,202$ 17,834
[1]Includes related party revenue of $733 and $4,703 for the three months ended March 31, 2024 and 2023, respectively.

DNA Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 840,440$ 944,073
Accounts receivable, net24,18917,157
Accounts receivable - related parties370742
Prepaid expenses and other current assets38,02139,777
Total current assets903,0201,001,749
Property, plant, and equipment, net195,992188,193
Operating lease right-of-use assets220,785206,801
Investments76,02178,565
Intangible assets, net77,40782,741
Goodwill47,90949,238
Other non-current assets60,62758,055
Total assets1,581,7611,665,342
Current liabilities:  
Accounts payable26,9959,323
Deferred revenue (includes $707 and $5,426 from related parties)33,61244,486
Accrued expenses and other current liabilities108,436110,051
Total current liabilities169,043163,860
Non-current liabilities:  
Deferred revenue, net of current portion (includes $123,549 and $119,053 from related parties)166,067158,062
Operating lease liabilities, non-current234,497221,835
Other non-current liabilities24,88424,433
Total liabilities594,491568,190
Commitments and contingencies (Note 8)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 200,000 shares authorized; none issued00
Common stock, $0.0001 par value (Note 6)202199
Additional paid-in capital6,445,0586,385,997
Accumulated deficit(5,456,439)(5,290,528)
Accumulated other comprehensive (loss) income(1,551)1,484
Total stockholders’ equity987,2701,097,152
Total liabilities and stockholders’ equity$ 1,581,761$ 1,665,342
DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEginkgobioworks.com
 INDUSTRYBiotechnology
 EMPLOYEES1292

Ginkgo Bioworks Holdings, Inc. Frequently Asked Questions


What is the ticker symbol for Ginkgo Bioworks Holdings, Inc.? What does DNA stand for in stocks?

DNA is the stock ticker symbol of Ginkgo Bioworks Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ginkgo Bioworks Holdings, Inc. (DNA)?

As of Thu Jul 18 2024, market cap of Ginkgo Bioworks Holdings, Inc. is 610.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DNA stock?

You can check DNA's fair value in chart for subscribers.

What is the fair value of DNA stock?

You can check DNA's fair value in chart for subscribers. The fair value of Ginkgo Bioworks Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ginkgo Bioworks Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ginkgo Bioworks Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether DNA is over valued or under valued. Whether Ginkgo Bioworks Holdings, Inc. is cheap or expensive depends on the assumptions which impact Ginkgo Bioworks Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNA.

What is Ginkgo Bioworks Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, DNA's PE ratio (Price to Earnings) is -0.71 and Price to Sales (PS) ratio is 2.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNA PE ratio will change depending on the future growth rate expectations of investors.